MGTX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 112587 min ago

@ $6.39

Išleistas: 14 vas. 2024 @ 16:30

Grąža: -21.28%

Ankstesnis signalas: vas. 13 - 16:30

Ankstesnis signalas: Pirkimas

Grąža: -2.44 %

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 21:48):

Stats
Šios dienos apimtis	56 104.00
Vidutinė apimtis	150 029
Rinkos kapitalizacija	319.89M
EPS	$0 ( 2024-03-12 )
Kita pelno data	( $-0.500 ) 2024-06-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.38
ATR14	$0.0120 (0.24%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-05	Forbes Alexandria	Sell	1 000	Ordinary Shares
2024-03-12	Forbes Alexandria	Sell	2 000	Ordinary Shares
2024-02-29	Giroux Richard	Sell	13 500	Ordinary Shares
2024-01-07	Zeldin Robert K	Sell	13 773	Ordinary Shares
2024-01-14	Giroux Richard	Buy	25 000	Ordinary Shares

INSIDER POWER
-6.04
Last 100 transactions
Buy: 8 402 826 \| Sell: 8 030 781

Tūris Koreliacija

Ilgas: 0.03 (neutral)

Trumpas: 0.20 (neutral)

Signal:(60.746) Neutral

MeiraGTx Holdings PLC Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

MeiraGTx Holdings PLC Koreliacija - Valiuta/Žaliavos

0.36
( neutral )

0.26
( neutral )

0.00
( neutral )

0.06
( neutral )

-0.14
( neutral )

MeiraGTx Holdings PLC Finansinės ataskaitos

Annual	2023
Pajamos:	$14.02M
Bruto pelnas:	$287 000 (2.05 %)
EPS:	$-1.490

FY	2023
Pajamos:	$14.02M
Bruto pelnas:	$287 000 (2.05 %)
EPS:	$-1.490

FY	2022
Pajamos:	$15.92M
Bruto pelnas:	$7.20M (45.21 %)
EPS:	$-3.16

FY	2021
Pajamos:	$37.70M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.800

Financial Reports:

No articles found.

MeiraGTx Holdings PLC

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.